Key statistics dashboard for GRI Bio, Inc. (GRI). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
Stock Data
| Price | $1.81 |
| Market Cap | $0M |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.04 |
| Price / Book | 0.32 |
| P/S | 0.00 |
| P/FCF | -0.02 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 10.30 |
| Quick Ratio | 10.30 |
| Cash Ratio | 9.95 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.39% |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 5.70 |
| Cash per share | 6.06 |
| FCF per share | -5.77 |
| Tangible Book Value per share | 5.70 |
| Dividend per share | 0.00 |
Related companies: ABP · BDRX · CANF · CLDI · CNSP · GNPX · INM
Explore sector: Healthcare · Biotechnology
More sections of GRI: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks